NCT00649298

Brief Summary

This study will assess clinical outcomes of extended weekly hours of haemodialysis (\>= 24 hours per week) compared with standard hours of haemodialysis (\<=18 hours/week) in people with ESKD.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started May 2008

Longer than P75 for phase_4

Geographic Reach
4 countries

40 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 25, 2008

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 1, 2008

Completed
1 month until next milestone

Study Start

First participant enrolled

May 1, 2008

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
Last Updated

December 3, 2019

Status Verified

December 1, 2019

Enrollment Period

6.2 years

First QC Date

March 25, 2008

Last Update Submit

December 1, 2019

Conditions

Keywords

Randomized Controlled TrialClinical TrialControlled Clinical TrialClinical Trial, Phase IVMulticenter StudyEnd Stage Kidney DiseaseHemodialysisRenal DialysisRenal Replacement TherapyNocturnal DialysisExtended dialysisQuality of LifeQuality Adjusted Life YearHypertrophy, Left VentricularBlood PressureHypertensionAnemiaHematinicsErythropoiesis Stimulating AgentsCost-utility AnalysisEconomic EvaluationHealth Care UtilisationHealth Care CostsHealth ExpendituresHospitalizationCost AnalysisCardiovascular DiseasesAcute Coronary SyndromeMyocardial InfarctionStrokeCerebrovascular DisordersMortalityArteriovenous FistulaArteriovenous Shunt, SurgicalThrombosisInfection

Outcome Measures

Primary Outcomes (1)

  • The primary end-point for this study is the difference in the change in quality of life between the two groups from randomisation to the 12 month follow-up as measured by the EQ-5D instrument.

    12 months from randomisation

Secondary Outcomes (5)

  • Survival and cardiovascular analyses

    12 months

  • Quality of life and patient acceptability

    12 months

  • Safety outcomes

    12 months

  • Costs associated with each intervention

    12 months

  • Changes in biochemical and haematological parameters

    12 months

Study Arms (2)

extended hours

EXPERIMENTAL

24 or more hours per week of hemodialysis

Procedure: haemodialysis

standard hours

ACTIVE COMPARATOR

18 or less hours per week of hemodialysis

Procedure: haemodialysis

Interventions

haemodialysisPROCEDURE

Comparison of different weekly duration of haemodialysis treatment

Also known as: Dialysis, Renal replacement therapy
extended hoursstandard hours

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Incident or prevalent patients requiring maintenance haemodialysis therapy for ESKD
  • Aged 18 years or older
  • Undergoing dialysis for 18 hours per week or less
  • Suitable for either extended or standard dialysis in the view of the treating physician
  • Agreeable to randomisation

You may not qualify if:

  • Life expectancy of less than 6 months
  • Definite plans to undergo renal transplantation within 12 months of entry to the study
  • Inability to complete quality of life questionnaire
  • Concomitant major illness that would limit assessments and followup
  • High chance that the patient will not adhere to study treatment and follow up in the view of the treating physician.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (40)

The Canberra Hospital

Canberra, Australian Capital Territory, Australia

Location

RPAH/Concord

Sydney, New South Wales, 2050, Australia

Location

Sydney Adventist Hospital

Sydney, New South Wales, 2076, Australia

Location

Liverpool Hospital

Sydney, New South Wales, Australia

Location

Sydney Dialysis Centre

Sydney, New South Wales, Australia

Location

Princess Alexandra Hospital

Brisbane, Queensland, Australia

Location

Royal Brisbane Hospital

Brisbane, Queensland, Australia

Location

Gold Coast Hospital

Gold Coast, Queensland, Australia

Location

Nambour General Hospital

Nambour, Queensland, Australia

Location

Royal Hobart Hospital

Hobart, Tasmania, Australia

Location

Austin Hospital

Melbourne, Victoria, Australia

Location

Monash Medical Centre

Melbourne, Victoria, Australia

Location

Royal Melbourne Hospital

Melbourne, Victoria, Australia

Location

Sir Charles Gairdner Hospital

Perth, Western Australia, Australia

Location

UBC

Vancouver, British Columbia, Canada

Location

St Michael's Hospital

Toronto, Ontario, M5B 1W8, Canada

Location

University Health Network

Toronto, Ontario, Canada

Location

Beijing Hospital of Traditional Chinese Medicine

Beijing, Beijing Municipality, China

Location

Beijing Tongren Hospital

Beijing, Beijing Municipality, China

Location

Civil Aviation General Hospital

Chaoyang District,, Beijing Municipality, China

Location

China-Japan Friendship Hospital

Chaoyang District, Beijing Municipality, China

Location

First Affiliated Hospital of Chinese PLA General Hospital

Haidian District, Beijing Municipality, China

Location

Beijing Hospital

Xicheng District, Beijing Municipality, China

Location

Peking University First Hospital

Xicheng District, Beijing Municipality, China

Location

Peking University People's Hospital

Xicheng District, Beijing Municipality, China

Location

Shenzhen Hospital of Peking University

Shenzhen, Guangdong, China

Location

Fourth Hospital Affiliated to Hebei Medical University

Shijiazhuang, Hebei, China

Location

Shijiazhuang First People's Hospital

Shijiazhuang, Hebei, China

Location

Third Hospital Affiliated to Hebei Medical University

Shijiazhuang, Hebei, China

Location

Zhengzhou University affiliated first hospital

Zhengzhou, Henan, China

Location

First Affiliated Hospital of Inner Mongolia, Baotou Medical College

Baotou, Inner Mongolia, China

Location

Zhongda Hospital, Southeast University

Nanjing, Jiangsu, China

Location

Fourth Hospital Affiliated to Jilin University (FAW General Hospital)

Changchun, Jilin, China

Location

Dalian Medical affiliated first hospital

Dalian, Liaoning, China

Location

Shanghai Ruijin Hospital

Shanghai, Shanghai Municipality, China

Location

The Chinese PLA Shanghai 85th Hospital

Shanghai, Shanghai Municipality, China

Location

The second affiliated hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Location

Huaxi Hospital of Sichuan University

Chengdu, Sichuan, China

Location

Auckland City Hospital

Auckland, New Zealand

Location

North Shore Hospital

Auckland, New Zealand

Location

Related Publications (7)

  • Jardine MJ, Zuo LI, Gray NA, de Zoysa J, Chan CT, Gallagher MP, Howard K, Hertier S, Cass A, Perkovic V; ACTIVE Dialysis Steering Committee. Design and participant baseline characteristics of 'A Clinical Trial of IntensiVE Dialysis': the ACTIVE Dialysis Study. Nephrology (Carlton). 2015 Apr;20(4):257-65. doi: 10.1111/nep.12385.

    PMID: 25529309BACKGROUND
  • Smyth B, van den Broek-Best O, Hong D, Howard K, Rogers K, Zuo L, Gray NA, de Zoysa JR, Chan CT, Lin H, Zhang L, Xu J, Cass A, Gallagher M, Perkovic V, Jardine M. Varying Association of Extended Hours Dialysis with Quality of Life. Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1751-1762. doi: 10.2215/CJN.06800619. Epub 2019 Oct 31.

  • Jardine MJ, Zuo L, Gray NA, de Zoysa JR, Chan CT, Gallagher MP, Monaghan H, Grieve SM, Puranik R, Lin H, Eris JM, Zhang L, Xu J, Howard K, Lo S, Cass A, Perkovic V; ACTIVE Dialysis Steering Committee; Paul. A Trial of Extending Hemodialysis Hours and Quality of Life. J Am Soc Nephrol. 2017 Jun;28(6):1898-1911. doi: 10.1681/ASN.2015111225. Epub 2017 Feb 1.

  • Zhan Z, Smyth B, Toussaint ND, Gray NA, Zuo L, de Zoysa JR, Chan CT, Jin C, Scaria A, Hawley CM, Perkovic V, Jardine MJ, Zhang L. Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study. BMC Nephrol. 2019 Jul 12;20(1):258. doi: 10.1186/s12882-019-1438-3.

  • Liao JL, van den Broek-Best O, Smyth B, Hong D, Vo K, Zuo L, Gray NA, Chan CT, de Zoysa J, Perkovic V, Jiang L, Jardine M. Effect of extended hours dialysis on sleep quality in a randomized trial. Nephrology (Carlton). 2019 Apr;24(4):430-437. doi: 10.1111/nep.13236.

  • Gray NA, Zuo L, Hong D, Smyth B, Jun M, De Zoysa J, Vo K, Howard K, Wang J, Lu C, Liu Z, Cass A, Perkovic V, Jardine M. Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial. Nephrology (Carlton). 2019 Oct;24(10):1056-1063. doi: 10.1111/nep.13530. Epub 2019 Apr 29.

  • Badve SV, Hawley CM, Johnson DW. Frequent versus standard hemodialysis. N Engl J Med. 2011 Mar 10;364(10):975; author reply 976. doi: 10.1056/NEJMc1100105. No abstract available.

MeSH Terms

Conditions

Kidney Failure, ChronicUremiaHypertrophy, Left VentricularHypertensionAnemiaCardiovascular DiseasesAcute Coronary SyndromeMyocardial InfarctionStrokeCerebrovascular DisordersArteriovenous FistulaThrombosisInfections

Interventions

DialysisRenal Replacement Therapy

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsCardiomegalyHeart DiseasesHypertrophyPathological Conditions, AnatomicalVascular DiseasesHematologic DiseasesHemic and Lymphatic DiseasesMyocardial IschemiaInfarctionIschemiaNecrosisBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesArteriovenous MalformationsVascular MalformationsCardiovascular AbnormalitiesVascular FistulaCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesFistulaEmbolism and Thrombosis

Intervention Hierarchy (Ancestors)

Chemistry Techniques, AnalyticalInvestigative TechniquesChemical PhenomenaTherapeutics

Study Officials

  • Vlado Perkovic, MBBS PhD

    The George Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 25, 2008

First Posted

April 1, 2008

Study Start

May 1, 2008

Primary Completion

July 1, 2014

Study Completion

October 1, 2014

Last Updated

December 3, 2019

Record last verified: 2019-12

Locations